Loading patent…
AssigneesAthera Biotechnologies AB, Dyax Corp.
InventorsKnut PETTERSSON, Ola CAMBER, Dan SEXTON, Andrew E. NIXON
Estimating the term…
The present invention relates to an antibody or antibody fragment capable of binding to phosphorylcholine and/or a phosphorylcholine conjugate, wherein the antibody or antibody fragment comprises a variable heavy chain (VH) domain and/or a variable light chain (VL) domain, and wherein— (a) the VH domain comprises an amino acid sequence that includes one, two or three complementarity determining regions (CDRs) selected from the group consisting of: a CDR1 sequence comprising an amino acid sequence having at least 20%, 40%, 60%, 80% or 100% sequence identity to the sequence of SEQ ID NO: 7; a CDR2 sequence comprising an amino acid sequence having at least 5%, 11%, 17%, 23%, 29%, 35%, 41%, 47%, 52%, 58%, 64%, 70%, 76%, 82%, 88%, 94%, or 100% sequence identity to the sequence of SEQ ID NO: 8; and a CDR3 sequence comprising an amino acid sequence having at least 11%, 22%, 33%, 44%, 55%, 66%, 77%, 88% or 100% sequence identity to the sequence of SEQ ID NO: 9 or 10; and/or (b) the VL domain comprises an amino acid sequence that includes one, two or three complementarity determining regions (CDRs) selected from the group consisting of: a CDR4 sequence comprising an amino acid sequence having at least 7.5%, 15%, 23%, 30%, 38%, 46%, 53%, 61%, 69%, 76%, 84%, 92% or 100% sequence identity to the sequence of SEQ ID NO: 11; a CDR5 sequence comprising an amino acid sequence having at least 14%, 28%, 42%, 57%, 71%, 85% or 100% sequence identity to the sequence of SEQ ID NO: 12; a CDR6 sequence comprising an amino acid sequence having at least 9%, 18%, 27%, 36%, 45%, 54%, 63%, 72%, 81%, 90% or 100% sequence identity to the sequence of SEQ ID NO: 13.
An antibody or antibody fragment capable of binding to phosphorylcholine and/or a phosphorylcholine conjugate,
The antibody or antibody fragment of any preceding claim wherein—
The antibody or antibody fragment according to any preceding claim, wherein—
The antibody or antibody fragment according to any preceding claim, wherein the VH domain, the VL domain, or preferably both of the VH and VL domains, comprise an amino acid sequence having 100% sequence identity to the, or one or more (such as all) of each, stated SEQ ID NO.
The antibody or antibody fragment according to any preceding claim, wherein the VH domain, the VL domain, or both of the VH and VL domains, comprise an amino acid sequence having less than 100%, but at least 80%, 85%, 90%, 95%, sequence identity to the, or one or more (such as all) of each, stated SEQ ID NO.
The antibody or antibody fragment according to any of preceding claim,
The antibody or antibody fragment according to any preceding claim wherein the VH domain and the VL domain are present in a linear polypeptide sequence.
The antibody or antibody fragment according to any preceding claim wherein the VH domain and the VL domain are each present in a separate polypeptide sequence, and preferably wherein the separate polypeptide sequence are directly or indirectly bound together (such as by one or more disulphide bonds between the separate polypeptide sequence).
The antibody or antibody fragment according to any preceding claim which is a human or humanized antibody or antibody fragment, such as a human or humanized monoclonal antibody.
The antibody or antibody fragment according to any preceding claim which is capable of binding to a phosphorylcholine conjugate.
A pharmaceutical composition comprising or consisting essentially of an antibody or an antibody fragment according to any of the preceding claims and a pharmaceutically acceptable carrier or excipient, optionally wherein the only antibodies or antibody fragments present in the composition are those defined by any of the preceding claims.
Dependencies are inferred from the claim text.